Japan's Ono Pharmaceutical will buy kinase inhibitor expert Deciphera for $2.4 billion. Novartis invests further in ...

During the Q&A portion of Amgen’s quarterly conference call Thursday, eight of the first nine questions were about the company’s investigational efforts in obesity. | The buzz about Amgen’s obesity ...

Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...

Eli Lilly has a Fever, and the only prescription is a new corporate partnership. | Eli Lilly has a Fever, and the only ...

As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a ...

Preeclampsia, a pregnancy complication typically associated with high blood pressure, is estimated to affect around one in ...

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based ...

Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat chronic obstructive pulmonary disease (COPD) could be ...

With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the ...

Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK ...

It’s no secret that U.S. biopharma companies rely on Chinese contractors to provide lab research and drug manufacturing ...